Key Takeaways

• David Betts created an AI communication app, “Talk To Me, Goose!”, for ALS patients to preserve their voices amid rapid disease progression.
• Current healthcare innovation suffers from regulatory delays, which can cost lives, particularly for terminal illnesses like ALS.
• The FDA has the tools to expedite patient access to treatments but often relies on outdated standards that impede timely solutions.

Healthcare Innovation and the ALS Challenge

ALS reshapes time in ways that are difficult to grasp for those outside the condition. The losses experienced by patients can occur unexpectedly, with speech often being one of the first faculties affected. Once lost, the opportunity to preserve a patient’s voice diminishes rapidly, with mere months to act.

After receiving an ALS diagnosis in 2024, David Betts, a former healthcare professional at Deloitte, began exploring communication aids for individuals who lose their ability to speak. His findings revealed a frustrating landscape filled with outdated technologies that lacked warmth and personality. This spurred him into action; despite having no formal engineering experience, he self-taught coding and built “Talk To Me, Goose!”, an AI-powered app designed to let ALS patients communicate using their own preserved voices. This innovation demonstrated a rapid development timeline, prompting a broader question: if progress can be made so quickly, why do other healthcare advancements lag?

The technology for Betts’ app, such as voice-cloning capabilities from firms like ElevenLabs, is readily available and has already aided hundreds of families. Unlike the technological barriers, the real issue in healthcare innovation lies in the culture of caution and regulatory delays. A poignant case shared by Betts illustrates this: a father with advanced ALS used his cloned voice to read a bedtime story, a moment that would have been lost had the app been subjected to prolonged testing or delays.

Research from economist Sam Peltzman highlights how regulatory processes can slow access to necessary treatments, often costing lives. With ALS patients typically surviving fewer than five years post-diagnosis, the urgency for timely solutions is critical. The FDA has mechanisms to accelerate drug approvals for terminal conditions, yet these are inconsistently utilized.

During COVID-19, the healthcare system showcased its capacity for rapid response. However, the return to traditional pacing has left many patients waiting for critical innovations. This inertia extends beyond drug approval to technology that remains stagnant in pilot tests, reflecting a broader systemic issue tied to a culture that prioritizes institutional safety over patient access.

Progressing with urgency involves aligning the importance of healthcare solutions with appropriate regulatory standards. Regulators and policymakers should employ strategies like conditional approvals, allowing access while trials continue.

For healthcare leaders, this means recognizing that patients do not have the luxury of time. If a tool can preserve a person’s ability to communicate and restore dignity, it should not be trapped in bureaucratic delays. As Betts reflects, the question to ask leaders is not about the potential cost of failure, but rather the human cost of inaction when patients are in desperate need. The balance of risk and benefit should reflect the severe stakes involved, especially for conditions as urgent as ALS.

The greater risk, ultimately, is not in moving too swiftly but in arriving too late.

The content above is a summary. For more details, see the source article.